Source: Annual Congress 2007 - Infectious lung and pleural diseases
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Makarevich, J. Pancratova (Minsk, Belarus). The improvement of protease-inhibitor imbalance in severe community-acquired pneumonia (CAP) by extracorporeal efferent detoxication methods (EEDM). Eur Respir J 2007; 30: Suppl. 51, 2728

Member's Comments

No comment yet.

Related content which might interest you: The correction of oxydant-antioxidant imbalance in severe community-acquired pneumonia (CAP) by extracorporeal efferent detoxication methods (EEDM) Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 The correction of immune disorders by extracorporeal efferent detoxication methods (EEDM) in severe community-acquired pneumonia (CAP) Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 Efficacy of combined therapy in severe community-acquired pneumonia (CAP) with efferent detoxication methods (EDM) vs. standard therapy by antibiotics (STA) Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005 Detection of liver function in patients with severe community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002 Comparison of costs of community-acquired pneumonia (CAP) treatment at patients with and without bronchial obstruction Source: Annual Congress 2011 - COPD management Year: 2011 Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 42s Year: 2007 Enhanced neutrophil response in patients with chronic bronchitis and community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 418s Year: 2002 Use of ceftriaxone/sulbactame for treatment of mild-to-severe community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Impact of neutrophil function on outcomes of community-acquired pneumonia (CAP) in patients with cancer Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication Year: 2007 Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients Source: Annual Congress 2011 - COPD management Year: 2011 Acute respiratory failure (ARF) and severe sepsis (SS) in community acquired pneumonia (CAP): different outcomes? Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia Year: 2009 Non-invasive ventilation (NIV) in community-acquired pneumonia CAP) and severe acute respiratory failure (ARF): Effectiveness and risk factors for failure and mortality Source: Annual Congress 2011 - Recent advances in noninvasive ventilation used for treating acute respiratory failure Year: 2011 Thyroid function in community-acquired pneumonia (CAP) patients: Pattern, relationship with severity and outcomes, need for invasive mechanical ventilation and vasopressor support Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Endothelial dysfunction and its corrections in patients with severe community-aquired pneumonia (CAP) Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020 Discharge delay in patients with community-acquired pneumonia (CAP) treated with a pneumonia critical pathway Source: Eur Respir J 2002; 20: Suppl. 38, 560s Year: 2002 Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 Community-acquired pneumonia as a cause of acute respiratory failure (ARF) in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 518s Year: 2005 Mortality in patients with ventilator-associated pneumonia (VAP) and severe sepsis is determined by the number of organ failures Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia Year: 2009 Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007 An unbalanced inflammatory response on admission impacts clinical stability in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011